In vitro potency of various polymyxin B components

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4490-4491

  Tam, Vincent H ^a   Cao, Henry ^a   Ledesma, Kimberly R ^a   Hu, Ming ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOLEUCINE POLYMYXIN B1; POLYMYXIN B; POLYMYXIN B2; POLYMYXIN B3; POLYMYXIN B4; POLYMYXIN DERIVATIVE; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; AMINO ACID ANALYSIS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; DRUG POTENCY; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B; PSEUDOMONAS AERUGINOSA;

EID: 80051826778     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00119-11     Document Type: Letter

References (10)

1. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing, 17th informational supplement. CLSI document M100-S17. CLSI, Wayne, PA.
2. He, J., et al. 2010. Variability of polymyxin B major components in commercial formulations. Int. J. Antimicrob. Agents 35:308-310.
3. Landman, D., S. Bratu, M. Alam, and J. Quale. 2005. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J. Antimicrob. Chemother. 55:954-957. (Pubitemid 40883181)
4. Landman, D., S. Bratu, and J. Quale. 2009. Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae. J. Med. Microbiol. 58:1303-1308.
5. Lee, J., G. Patel, S. Huprikar, D P Calfee, and S G Jenkins. 2009. Decreased susceptibility to polymyxin B during treatment for carbapenemresistant Klebsiella pneumoniae infection. J. Clin. Microbiol. 47:1611-1612.
6. Lolans, K., T W Rice, L S Munoz-Price, and J P Quinn. 2006. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob. Agents Chemother. 50:2941-2945. (Pubitemid 44396395)
7. Orwa, J A, et al. 2001. Isolation and structural characterization of polymyxin B components. J. Chromatogr. A 912:369-373. (Pubitemid 32234375)
8. Tam, V H, et al. 2010. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54:1160-1164.
9. Tam, V H, J. Hou, A L Kwa, and R A Prince. 2009. Comment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J. Antimicrob. Chemother. 63:627-629.
10. Yuan, Z, and V H Tam. 2008. Polymyxin B: A new strategy for multidrug-resistant Gram-negative organisms. Expert Opin. Investig. Drugs. 17:661-668. (Pubitemid 351843610)